We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for DexCom, Inc. (DXCM - Free Report) . Shares have added about 17.7% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is DXCM due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
DexCom reported loss of 32 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate. Also, the figure was narrower than the loss of 49 cents reported in the year-ago quarter.
Total revenues grew 29.6% to $184.4 million from $142.3 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $173 million.
Segmental Details
Sensor revenues & other revenues (72% of total revenues) grew 30% on a year-over-year basis to $131.9 million. Transmitter revenues (20%) increased 28% from the prior-year quarter’s tally to $37.7 million. Receiver revenues (8%) grew 26% year over year to $14.8 million.
Operational Details
DexCom generated gross margin (as a percentage of revenues) of 64.5%, which contracted 160 basis points (bps) year over year. Margins were under pressure due to an inventory change and shift toward OUS and Medicare.
International business displayed continued growth in the quarter, up 49% on a year-over-year basis.
Research and development (R&D) expenses totaled $44.8 million in the quarter, down 6.9% year over year.
Selling, general and administrative expenses totaled $104.8 million in the reported quarter, increasing 21.3% year over year.
Guidance
DexCom raised the full-year 2018 guidance.
The company expects 2018 revenues in the range of $850-$860 million, up from the previous range of $830-$850 million.
Gross profit margin is projected in the band of 65% to 68%.
Operating expenses, excluding investments in non-intensive programs, are expected to increase 10% from 2017.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month. There have been four revisions higher for the current quarter compared to seven lower.
At this time, DXCM has an average Growth Score of C. Its Momentum is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for momentum investors than growth investors.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, DXCM has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for DexCom, Inc. (DXCM - Free Report) . Shares have added about 17.7% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is DXCM due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
DexCom reported loss of 32 cents per share in the first quarter of 2018, in line with the Zacks Consensus Estimate. Also, the figure was narrower than the loss of 49 cents reported in the year-ago quarter.
Total revenues grew 29.6% to $184.4 million from $142.3 million in the year-ago quarter. Revenues surpassed the Zacks Consensus Estimate of $173 million.
Segmental Details
Sensor revenues & other revenues (72% of total revenues) grew 30% on a year-over-year basis to $131.9 million. Transmitter revenues (20%) increased 28% from the prior-year quarter’s tally to $37.7 million. Receiver revenues (8%) grew 26% year over year to $14.8 million.
Operational Details
DexCom generated gross margin (as a percentage of revenues) of 64.5%, which contracted 160 basis points (bps) year over year. Margins were under pressure due to an inventory change and shift toward OUS and Medicare.
International business displayed continued growth in the quarter, up 49% on a year-over-year basis.
Research and development (R&D) expenses totaled $44.8 million in the quarter, down 6.9% year over year.
Selling, general and administrative expenses totaled $104.8 million in the reported quarter, increasing 21.3% year over year.
Guidance
DexCom raised the full-year 2018 guidance.
The company expects 2018 revenues in the range of $850-$860 million, up from the previous range of $830-$850 million.
Gross profit margin is projected in the band of 65% to 68%.
Operating expenses, excluding investments in non-intensive programs, are expected to increase 10% from 2017.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month. There have been four revisions higher for the current quarter compared to seven lower.
DexCom, Inc. Price and Consensus
DexCom, Inc. Price and Consensus | DexCom, Inc. Quote
VGM Scores
At this time, DXCM has an average Growth Score of C. Its Momentum is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for momentum investors than growth investors.
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, DXCM has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.